Over the years, the nomenclature of this entity has been complicated. It has been alternatively called cranial arteritis or temporal arteritis, reflecting the most commonly affected vessels.
The positive opinion is based on results from the pivotal Phase 3 SELECT-GCA trial that evaluated the efficacy and safety of upadacitinib in adults with giant cell arteritis (GCA) 1 The primary ...
EMA committee recommends approval of AbbVie’s upadacitinib to treat adults with giant cell arteritis
AbbVie announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of upadacitinib (Rinvoq; 15 mg, once ...
The most dramatic symptoms of GCA (for example, visual loss) result directly from the inflammation of the large- and medium-sized cranial vessels ... Giant cell arteritis is a systemic vasculitis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback